Sunday, July 3, 2022
    HomeHealthHealth tech M&A is heating up & 23andMe's cancer drug play

    Health tech M&A is heating up & 23andMe’s cancer drug play


    You’re studying the net version of STAT Well being Tech, our information to how tech is remodeling the life sciences. Sign up to get this newsletter delivered in your inbox each Tuesday and Thursday. 

    During the last 12 months, Katie dove into the science and enterprise of steady glucose screens. For a complete have a look at what’s forward for the gadgets — not only for diabetes sufferers, however the broader public — seize a duplicate of our new STAT Report.

    Biosensors at three-letter conferences


    Talking of CGM, gadget maker Dexcom’s presentation at this week’s all-virtual JP Morgan Healthcare Convention lastly confirmed ahead motion on its next-generation continuous glucose monitor, the G7. The corporate filed with the FDA in late 2021, and shared information from its submission at JPM, together with outcomes exhibiting that the gadget meets the requirements to feed its information into automated insulin pumps. “Our present techniques have been designed to readily join with the automated insulin supply developments which are going to be popping out over the subsequent a number of years,” stated CEO Kevin Sayer. “I’d even go as far as to say sharing information could also be some of the important improvements this firm has executed over its historical past.”

    The information comes as Dexcom’s major competitor Abbott made a daring announcement final week at CES: The corporate will launch a brand new line of disposable direct-to-consumer biosensors dubbed Lingo. The primary gadget will measure ketones, focusing on followers of the faddish keto weight loss program, though observers counsel such sensing might be a gorgeous addition for sufferers who diligently observe their numbers to keep away from diabetic ketoacidosis. The corporate additionally plans client glucose and lactate biosensors, geared toward serving to folks optimize diet and train. As glucose monitoring firms goal to scoop up an increasingly broad user base, Dexcom could need to determine whether or not it would give attention to making the absolute best product for folks with diabetes, or reaching the most important doable market by bringing in a brand new era of sensor-happy customers.


    In different information at JPM…

    • Teladoc nudged income projections for the 2021 fiscal 12 months up barely to $2.03 billion, as CEO Jason Gorevic doubled down on the corporate’s imaginative and prescient for “entire individual care”: just about treating sufferers’ psychological, bodily, continual and complicated wants and connecting them to brick-and-mortar companies when wanted.
    • Executives with Oak Road Well being, a supplier of digital and in-person major care to Medicare sufferers, stated they may open the throttle on their growth plans in 2022, including 70 new well being facilities. That may give the corporate a complete of 200 clinics nationwide, along with a digital specialty session enterprise it added via the acquisition of RubiconMD.  The corporate can be going through some headwinds, nevertheless, together with a Division of Justice inquiry into whether or not it violated the False Claims Act associated to third-party advertising and marketing actions.

    Developing as we speak at JPM: Worth-based care software program firm Aledade is predicted to announce its first acquisition at JPM Tuesday: Iris Healthcare, which sells help for superior care planning. Aledade was based by Farzad Mostashari, the highest federal well being IT official beneath President Barack Obama.

    23andMe’s most cancers play

    Final week, 23andMe started clinical trials of its first wholly-owned drug, a most cancers immunotherapy — a big turning level for an organization attempting to develop into drug improvement from its roots in client genetic testing. It’s the second most cancers drug the corporate has superior into human trials, following an immunotherapy developed in partnership with GSK. However whereas 23andMe dives headlong into pharma timelines, there’s nonetheless room for extra on the buyer aspect: On Monday, the corporate introduced it has acquired FDA clearance for its third DTC genetic check, for a hereditary prostate most cancers marker. It’s the longest of lengthy performs, nevertheless it’ll be fascinating to see if the corporate can efficiently promote prevention and remedy on the similar time, for a similar illness.

    One small step for information requirements…

    The Workplace of the Nationwide Coordinator has launched a technical specification for recording affected person addresses in digital data. It feels like a small factor, however formatting variations steadily lead to an incapacity to precisely establish sufferers and observe their data. The brand new specification, dubbed Venture [email protected], will assist advance interoperability throughout well being care IT techniques and assist organizations hyperlink affected person data held by totally different suppliers and insurers, as long as all of them undertake the requirements. Talking of requirements, ONC has additionally launched its revised interoperability guide.

    M&A is heating up

    • Withings is buying Impeto Medical, the maker of a expertise to detect small fiber neuropathy associated to chemo in addition to illnesses resembling diabetes and Parkinson’s. Withings plans to include the expertise into its at-home physique scan gadget to detect frequent circumstances.
    • R1 RCM, a maker of expertise to enhance supplier monetary efficiency, is buying the Atlanta-based revenue-cycle firm Cloudmed in an all-stock transaction. The deal values Cloudmed at $4.1 billion.
    • The voice assistant firm Speak2Family is acquiring rival SoundMind for an undisclosed sum. Each firms use voice assistants to assist seniors with each day routines.
    • LG is equipping all its 2021 and 2022 good TVs with a telehealth app from the senior-focused platform Independa. The app will enable clients to schedule and conduct telehealth appointments via their TVs.
    • The in-home care firm Medically Residence raised $110 million in new funding from Baxter WorldwideWorld Medical Response and Cardinal Well being. Its present supplier companions, Mayo Clinic and Kaiser Permanente, additionally kicked in more cash.
    • Little Otter, a digital psychological well being supplier for youngsters and households, raised $22 million in a Collection A spherical led by CRV. The corporate will use the funding to broaden past present availability in California, Colorado, North Carolina, and Florida.

    What we’re studying

    Source link

    Related articles

    Stay Connected


    Latest posts